Therapeutic antibodies in ophthalmology

Autor: Hervé Watier, Coralie Pinault, Gilles Paintaud, Charlotte Magdelaine-Beuzelin

Publikováno v: mAbs
mAbs, Taylor & Francis, 2010, 2 (2), pp.176-180

International audience; More than a century after the first successful use of serotherapy, antibody-based therapy has been renewed by the availability of recombinant monoclonal antibodies. As in the past, current clinical experience has prompted new

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90c28a60b2666456c3cdd3b5ec4302ce
https://doi.org/10.4161/mabs.2.2.11205

The homozygous FcγRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes

Autor: Chloé Charroing, Dominique Lasne, Claire Pouplard, Hervé Watier, Charlotte Magdelaine-Beuzelin, Yves Gruel

Publikováno v: Blood. 104:2791-2793

We hypothesized that Fcγ receptor IIIa (FcγRIIIa), a polymorphic receptor for the Fc portion of immunoglobulin G (IgG) other than FcγRIIa, was involved in heparin-induced thrombocytopenia (HIT). FcγRIIa-131 and FcγRIIIa-158 genotypes were determ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d540ae18a8698d30f54419b97ad15967
https://doi.org/10.1182/blood-2004-01-0058

[Neonatal Fc receptor, key control of immunoglobulins biodistribution]

Autor: Charlotte, Magdelaine-Beuzelin, Marc, Ohresser, Hervé, Watier

Publikováno v: Medecine sciences : M/S. 25(12)

In 1969, Brambell, while studying the long serum half-life of IgG and their ability to cross the materno-foetal barrier, attributed these two properties to the existence of a specific Fc receptor, which was later denominated FcRn for neonatal Fc rece

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b473af43ffe17f599d1078a1745792cf
https://pubmed.ncbi.nlm.nih.gov/20035678

IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab

Autor: Margaret Goodall, Filip Baert, Hervé Watier, Maja Noman, Severine Vermeire, Marc Ohresser, Charlotte Magdelaine-Beuzelin, Danielle Degenne, Paul Rutgeerts, Maire-Paule Lefranc, Roy Jefferis, Gert Van Assche, Jean-Michel Dugoujon

Publikováno v: Pharmacogenetics and Genomics
Pharmacogenetics and Genomics, Lippincott, Williams & Wilkins, 2009, 19 (5), pp.383-387. ⟨10.1097/FPC.0b013e32832a06bf⟩
Pharmacogenet. Genomics
Pharmacogenet. Genomics, 2009, 19 (5), pp.383-387

International audience; Objective The chimeric anti-tumor necrosis factor-alpha antibody infliximab is known to induce antibodies-to-infliximab (ATI) in some treated patients. Immunogenicity in murine variable domains is expected; however, constant d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0f358989f7db50da640b1f1bd369408
https://pubmed.ncbi.nlm.nih.gov/19319024

Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis

Autor: Charlotte Magdelaine-Beuzelin, Jean-Camille Méric, Gilles Paintaud, Jean-Pierre Valat, Denis Mulleman, Emilie Ducourau, Philippe Goupille

Publikováno v: Arthritis Research and Therapy
Arthritis Research and Therapy, BioMed Central, 2009, 11 (6), pp.R178. ⟨10.1186/ar2867⟩
13ème congrès annuel de la Société Française de Pharmacologie et de Thérapeutique
13ème congrès annuel de la Société Française de Pharmacologie et de Thérapeutique, Apr 2009, MARSEILLE, France
Fundamental and Clinical Pharmacology
Fundamental and Clinical Pharmacology, Wiley, 2009, 23, pp.29-29

International audience; INTRODUCTION: Adjustment of infliximab dosage for individuals may be useful in improving therapeutic response in rheumatoid arthritis (RA). Herein, we aimed to determine whether measurement of infliximab serum concentration mo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b834f1d8ce3484d2a118ce7f77dea0af
https://hal.science/hal-00616867